Verndari, Inc.

12/01/2021

We are pleased to announce a breakthrough mRNA stabilization discovery. Findings announced by Verndari at World Vaccine and Immunotherapy Congress West Coast may help overcome technical, economic and political hurdles to global COVID-19 vaccine distribution.

Using Verndari’s proprietary formulation, we have been able to dry, store at room temperature and reconstitute 100% of the activity of mRNA vaccines in vitro. These patent-pending formulations have the potential for use with all mRNA vaccines, therapeutics & delivery methods.

“We believe this discovery may prove instrumental in helping healthcare leaders overcome the technical, economic and political hurdles that have impeded universal access to COVID-19 vaccines and other life-saving mRNA vaccines and therapeutics,” said Daniel Henderson, CEO and chief scientific officer at Verndari.

Learn more:

Verndari, Inc. announces mRNA breakthrough: room temperature stabilized formulation has potential for use with COVID-19 and other mRNA vaccines.

11/04/2021

"There’s nothing more gratifying than being able to combine something you really care about with the goal of making an impact on the world.”

Amy Van Prooyen, Esq., is an alumna of the University of San Francisco School of Law and vice president of corporate communication and legal affairs at Verndari. Learn more about Amy’s varied passions and how she’s incorporated them into her role at Verndari.

A pioneer in litigation communication brings her expertise to the vaccine world.

10/12/2021

StartUs Insights included Verndari's VaxiPatch™ in its top 5 Vaccine Distribution Solutions after analyzing more than 150 healthtech startups.

Verndari is a California-based biotech startup that develops VaxiPatch, a complete single-dose vaccination kit with antigen and delivery systems. The thermostable VaxiPatch eliminates the need for cold chains and uses a painless microneedle patch application for vaccine delivery via the skin. This easy-to-use vaccine technology can potentially be self-applied and is dose-sparing.

By reimagining vaccines from development through inoculation, Verndari aims to improve global health.

Discover 5 global startups & scaleups in this data-driven report & learn how their vaccine distribution solutions impact your business!

09/20/2021

Verndari is proud to announce that we were selected as a quarterfinalist in the Breakthrough COVID-19 Technology category for a UCSF Health Award! The UCSF Health Awards honor outstanding health technologies and innovations dramatically transforming health care.

Verndari’s VaxiPatch is an easy-to-use, painless, highly effective and dose-sparing microarray patch (MAP) system. We are grateful to the team at UCSF Health Hub for this recognition. Learn more: https://www.ucsfhealthhub.com/award-finalists/gbvXPdwg

12/11/2020

Research underway at UC Davis provides a window into the vaccine world from development to testing—including our ™. Verndari, Inc.'s painless, thermostable microneedle patch is transforming delivery. Learn more in this feature from Comstock's magazine:

UC Davis researchers join the global race for a COVID-19 vaccine

11/30/2020

Verndari, Inc. is proud to be among the Bay Area innovators addressing and specifically, innovation in vaccine delivery. The San Francisco Chronicle highlights how our ™ microneedle patch could serve as a 'shelter in place' delivery system strategy—mailable, thermostable and self-administered.

A hunt is under way in the Bay Area to find medicines and vaccines for the coronavirus. Here are some of the most promising treatments being studied.

08/28/2020

Our Verndari, Inc. VaxiPatch™ and the other alternative technologies for which the Biomedical Advanced Research and Development Authority (BARDA) recently announced its support have something important in common—they're themostable, making them easier to store and deliver. Learn more from CNN: https://cnn.it/3hErFTI

The US federal government said Wednesday it’s investing nearly $2.5 million in efforts to create a needle-free coronavirus vaccine.

08/26/2020

Verndari, Inc. is pleased to announce that we're partnering with the Biomedical Advanced Research and Development Authority (BARDA) to accelerate work on our VaxiPatch™ microneedle dermal delivery patch. Today, four companies nationally have received DRIVe program support to develop alternative vaccine delivery technologies for infectious diseases such as .

Learn more: https://bit.ly/3jksXnA

08/19/2020

The desired immune response, produced with a 15-fold reduction in the amount of antigen—these preclinical study results using our Verndari, Inc. VaxiPatch™ to administer a flu vaccine are now published in the Elsevier journal .

Learn how the microneedle dermal patch may enable faster, lower cost vaccine development across multiple infectious diseases including :

This work introduces VaxiPatch, a novel vaccination system comprised of subunit glycoprotein vaccine antigens, adjuvants and dermal delivery. For this…

08/17/2020

Your skin can play a key role in your immune response. PBS NewsHour shares how patch technology—including Verndari, Inc.'s VaxiPatch™—is designed to take advantage of this through a dose-saving, thermostable microneedle dermal delivery system that could make it less expensive than traditional methods: https://to.pbs.org/2XnxPzD

05/17/2020

Pleased to see Verndari’s mission to transform vaccines highlighted front and center in today’s San Francisco Chronicle. Our patented, single dose vaccination kit uses a painless dermal patch to deliver vaccine, eliminating injection, vaccine cold storage and allowing high-volume production. Right now, we’re testing it with a potential COVID-19 vaccine. Learn more:

Thanks to the Bay Area’s proximity to leading health care centers and Silicon Valley, local companies could get a leg up in the global race to develop a vaccine.

05/02/2020

"The vaccine uses a skin patch with a metal microneedle to deliver the vaccine. The company says the technology eliminates the need for refrigeration. It could also allow for rapid mass production and potentially be self-administered."

Preclinical testing began this week at the UC Davis Mouse Biology Program.